Clinical Trials Logo

Relapsed Adult AML clinical trials

View clinical trials related to Relapsed Adult AML.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03932318 Withdrawn - Clinical trials for Acute Myeloid Leukemia

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Start date: March 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in combination with venetoclax and azacitidine for patients with CD33 positive AML. (Phase I portion) 2. To assess the percentage of patients with CR, CRh, CRi, MLFS or Overall Response (CR + CRh + CRi + MLFS), up to 6 months after the start of treatment without receiving other AML therapies.. (Phase 2 portion)